Foley told the sales team at their meeting in Nashville about a month ago, that RVNC has plenty of cash and they have nothing to be concerned with! There are VC companies who are shorting the RVNC stock and driving it down. It will take a few months for the stock to recover.
With Daxi now costing practices the same as Botox, the goal is for injectors to price Daxi at the same price as Botox to the patient. This strategy is now winning and both patients and injectors are loving Daxi!
Per Q3 sales forecast, I support Dew’s numbers! The sales team did not hit their Q3 target revenue as a whole which is typically higher than WS forecast. Many of the sales reps did hit their numbers, but others did not! Q4 sales are going very well, but its is hard to determine if it is the quarter or if the lower price is driving sales.
News 
Market Data 
Discover 
